RxDoctor Payments Data

Howard Fugate, MD

Internal Medicine · Harrisburg, PANPI 1093748931

Payments from drug & device makers

$528in general payments, 2019–2025

Across 18 payments — averaging $29.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$323
  • Otsuka America Pharmaceutical, Inc.$144
  • Eisai Inc.$13
  • Johnson & Johnson$13
  • Merck$12
  • Lilly USA, LLC$12
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$528100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$528 in reported general payments places this provider in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$260,319
Medicare patients
1,082
Services billed
3,363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$58,957
OzempicSemaglutide23$26,892
JardianceEmpagliflozin13$14,346
MyrbetriqMirabegron20$5,657
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen39$2,756
Atorvastatin Calcium152$2,567
Fentanyl32$2,138
Amiodarone Hcl15$1,867
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen26$1,811
Novolog FlexpenInsulin Aspart13$1,612
Omega-3 Acid Ethyl Esters13$1,466
Bumetanide31$1,455
Levothyroxine Sodium163$1,413
Losartan Potassium89$1,124
Duloxetine Hcl16$1,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$58,95788 claims
Novo NordiskOzempic$323$26,89223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Harrisburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →